Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
921 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT01949805 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera(PROUD-PV) | completed | Phase 3 | 257 | AOP Orphan Pharmaceuticals AGINDUSTRY |
| 14 |
| Nov 28, 2016 |
| clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT00066807 | Premenopausal Endocrine Responsive Chemotherapy Trial(PERCHE) | terminated | Phase 3 | 29 | ETOP IBCSG Partners FoundationNETWORK | 3 | Oct 28, 2016 | clinicaltrials |
| NCT00744497 | Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer(READY) | completed | Phase 3 | 1,930 | Bristol-Myers SquibbINDUSTRY | 25 | Oct 17, 2016 | clinicaltrials |
| NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer(SYNERGY) | completed | Phase 3 | 1,022 | Achieve Life SciencesINDUSTRY | 12 | Oct 14, 2016 | clinicaltrials |
| NCT00182819 | Radiation Therapy or Temozolomide in Treating Patients With Gliomas | completed | Phase 3 | 709 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 19 | Oct 12, 2016 | clinicaltrials |
| NCT01419197 | A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy(TH3RESA) | completed | Phase 3 | 602 | Hoffmann-La RocheINDUSTRY | 22 | Oct 12, 2016 | clinicaltrials |
| NCT01578655 | Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer(AFFINITY) | completed | Phase 3 | 630 | Achieve Life SciencesINDUSTRY | 8 | Oct 12, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00861614 | Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 988 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 30, 2016 | clinicaltrials |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk(REDUCE) | completed | Phase 3 | 8,231 | GlaxoSmithKlineINDUSTRY | 42 | Sep 23, 2016 | clinicaltrials |
| NCT01035229 | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.(EVOLVE-1) | completed | Phase 3 | 546 | Novartis PharmaceuticalsINDUSTRY | 18 | Sep 22, 2016 | clinicaltrials |
| NCT00022516 | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer(22-00) | completed | Phase 3 | 1,086 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 16, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 837 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 18, 2016 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00738530 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | completed | Phase 3 | 649 | Hoffmann-La RocheINDUSTRY | 18 | Jun 23, 2016 | clinicaltrials |
| NCT01494506 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer(NAPOLI-1) | completed | Phase 3 | 417 | Merrimack PharmaceuticalsINDUSTRY | 15 | Jun 17, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | completed | Phase 3 | 640 | Threshold PharmaceuticalsINDUSTRY | 13 | Jun 2, 2016 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT00402519 | APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer | unknown | Phase 3 | 1,300 | University of Erlangen-Nürnberg Medical SchoolOTHER | 5 | May 13, 2016 | clinicaltrials |
| NCT00305188 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | completed | Phase 3 | 879 | SanofiINDUSTRY | 13 | May 4, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01082549 | Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)(ECLIPSE) | completed | Phase 3 | 780 | SanofiINDUSTRY | 14 | Mar 17, 2016 | clinicaltrials |
| NCT01151410 | An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age | completed | Phase 3 | 208 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 7, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT01250379 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) | completed | Phase 3 | 494 | Hoffmann-La RocheINDUSTRY | 13 | Feb 11, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT00699517 | A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies | completed | Phase 3 | 355 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | completed | Phase 3 | 124 | Hoffmann-La RocheINDUSTRY | 1 | Dec 10, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT01509781 | Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study | unknown | Phase 3 | 400 | National Institute of Oncology, HungaryOTHER | 1 | Oct 6, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials